Amyloid myopathy …

Jasvinder Chawla MD MBA

Neuromuscular Disorders

Updated 05.12.2023
Released 10.27.2011
Expires For CME 05.12.2026

Amyloid myopathy

Author: Jasvinder Chawla MD MBA

See Contributor Disclosures

Editor: Michael K Hehir MD

Amyloid myopathy

In This Article

Quick Link

Introduction

Overview

Symptoms of primary systemic amyloidosis include neuropathy, myopathy, and cardiac or renal insufficiency; multiple organ systems are often involved. Amyloidosis can involve both the central nervous system and peripheral nerves. Amyloid myopathy is a rare manifestation of primary systemic amyloidosis. It is less well recognized that amyloid can directly infiltrate and weaken skeletal muscle. Like most other myopathies associated with systemic disorders, it is manifest by proximal limb muscle weakness and increased serum levels of creatine kinase.

Key points

	• Amyloid myopathy is one of the uncommon manifestations of systemic amyloidosis.
	• The symptoms are usually nonspecific, typically including progressive proximal limb weakness with an increased creatine kinase level, macroglossia, and muscle pseudohypertrophy.
	• The diagnosis of amyloid myopathy is usually overlooked, and it is often misdiagnosed as inflammatory myopathy, even when a muscle biopsy is available.
	• Amyloid myopathy associated with a plasma cell dyscrasia is a rare cause of muscle hypertrophy. It can be a challenging diagnosis because pathological findings are often elusive.
	• When suspecting amyloid myopathy, Congo red staining and either an immunohistochemical assay or immunofluorescence study should be performed.
	• Amyloid myopathy should be a consideration in adults with progressive neuromuscular weakness of uncertain cause.
	• Recognition of amyloid myopathy is important because clinical symptoms may respond to melphalan and prednisone therapy

Historical note and terminology

The first recognized patient with amyloid-associated muscle involvement was reported by Lubarsch in 1929; both vascular and interstitial deposits were seen in skeletal muscle and heart (26). It has now been reported in three of the largest series that myopathy is rarely caused by amyloidosis (14; 39; 51). Classification of amyloidosis is based in part on the chemistry of the amyloid fibrils. Amyloidosis accompanying plasma cell dyscrasia is characterized by fibrils containing a component of immunoglobulin light chains. The oval masses may contribute to muscular hypertrophy and to the formation of nodules within the muscles. These nodules may also contribute to muscle weakness by compression of nearby muscle fibers (07).

Clinical manifestations

Presentation and course

Symptoms of systemic amyloidosis include neuropathy, myopathy, and cardiac or renal insufficiency; there is often multiple-organ involvement. Myopathy is a rare clinical manifestation in primary systemic amyloidosis and, to some extent, an underdiagnosed entity (31; 23; 13). Proximal weakness, muscle stiffness, pseudohypertrophy, and myalgia constitute the principal features.

The initial manifestation may predominantly consist of proximal muscle weakness. Other features due to amyloid deposition at different sites may develop later (14). Pseudohypertrophy, nodular lesions of muscles, and macroglossia are often lacking. This syndrome usually develops in cases with well-recognized generalized amyloidosis (41). Carr and colleagues described the first case in literature in a patient with symptomatic myopathy and neuropathy with confirmation of tissue amyloid deposition (from sural nerve and vastus lateralis muscle) (04).

The mean onset age of amyloid myopathy is 60 years. Ninety percent of patients report proximal weakness. This may be associated with macroglossia and muscle pseudohypertrophy in almost a third of the patients. Macroglossia sometimes precludes closure of the mouth; dysphagia and hoarseness may also occur. Dysphagia is present in 25% of patients (39; 42; 05). The clinical importance of macroglossia in a patient with dyspnea and cardiomyopathy is highlighted in a case report (15).

The most prominent findings are abnormal firmness and pseudohypertrophy of the musculature and palpable tumors within muscles (29; 57; 40). Muscle weakness caused by amyloid myopathy has also been described in the absence of pseudohypertrophy. It can also manifest with diffuse muscle hypertrophy on general physical examination (54). The clinical picture then comprises proximal limb weakness with pronounced atrophy. As expected, with any proximal muscle weakness, patients have difficulty raising the arms overhead or climbing stairs (19). Weakness of the neck flexors, as well as shoulder and thigh muscles with atrophy, is also common (24; 57; 40).

Muscle claudication is rare but has been recognized in patients with amyloid myopathy. It results from progressive vascular deposition of amyloid and leads to ischemia and obstruction of small vessels. These patients have been misdiagnosed as having giant cell arteritis and inappropriately treated with high-dose corticosteroids (57; 45).

The presence of amyloid myopathy with myeloma and lytic bone disease has been recognized. Santos and colleagues reported a patient with amyloidosis associated with multiple myeloma who showed clinical characteristics of pseudomyopathy (44). Amyloid myopathy involving the diaphragm and resulting in diaphragmatic failure requiring ventilatory support is also well recognized (52; 43; 01). Amyloidosis may cause adult-onset sensorimotor peripheral neuropathy. Unlike neuropathy secondary to amyloid deposition, myopathy is infrequently described (55).

Amyloid myopathy is frequently misdiagnosed as an inflammatory myopathy, especially polymyositis because of similarities in clinical, neurophysiological, and muscle biopsy findings. Both can show similar inflammatory infiltrates on muscle biopsy, especially when only the hematoxylin-eosin stain is used (27; 17; 20; 09; 32). Spuler and colleagues found that routine use of Congo red-stained sections increased the frequency of a diagnosis of amyloid myopathy almost 10-fold.

Failure to recognize amyloid myopathy precludes patients from potentially life-prolonging treatment. Congo red staining and immunohistochemical analysis of tissue could prevent misdiagnosis (27). In middle-aged or elderly patients with proximal limb weakness, the diagnosis of amyloid myopathy should be considered (19).

Tanabe and colleagues reported an autopsy-proven case of systemic secondary amyloid A (AA) amyloidosis with muscle amyloid angiopathy, possibly induced by psoriasis vulgaris (53).

Prognosis and complications

Likelihood of survival with this disease remains poor, with a median survival rate of 1 to 2 years. Congestive heart failure and nephrotic syndrome are predominant causes of death. Without early therapy, however, the disease has a dismal prognosis (21). A case report from Ohtsuka and colleagues emphasized the fact that when amyloidosis is suspected and there is evidence of muscle injury, a muscle biopsy should be performed (36).

Clinical vignette

A 71-year-old woman with a history of primary systemic amyloidosis noted worsening fatigue, claudication, and weakness in her legs more than arms and hands over the past 2 years. Neurologic examination revealed symmetrical proximal limb weakness in lower and upper extremities with preserved tendon reflexes. Examination showed no other abnormalities. EMG study revealed myopathic findings and CK values were borderline elevated. Bone marrow biopsy revealed an IgG kappa monoclonal gammopathy. MRI of the thighs revealed increased T2 signal of subcutaneous fat and tissue between muscle groups with only minimal signal intensity alteration of muscle. Muscle biopsy revealed characteristic apple-green birefringent amyloid deposits surrounding individual muscle fibers in Congo red-stained sections. Electron microscopy demonstrated amyloid filaments in close apposition to muscle fibers exhibiting excessive corrugations of the sarcolemmal membrane. Treatment included prednisone 60 mg daily and cyclophosphamide 150 mg daily with improvement of symptoms.

Biological basis

Etiology and pathogenesis

Plasma cell dyscrasia or multiple myeloma is associated with amyloid myopathy in the majority of patients (12; 02; 08). The mechanisms by which the amyloid deposits weaken the skeletal muscles remain unclear.

The clinical phenotype and muscle histology are well known, but the pathophysiological mechanisms remain poorly understood. Amyloid denotes a waxy, amorphous, and eosinophilic material. Amyloidosis can involve multiple organs, including kidney, heart, skin, joints, peripheral nerve, and skeletal muscle. The most common form of amyloidosis in the United States is termed “light chain amyloidosis,” which results from deposition of monoclonal antibody light chains. Of the three types of systemic amyloidosis, primary systemic amyloidosis is the type that most often involves skeletal muscle. Amyloid is generally not deposited in muscle in the secondary type (amyloid A protein) and can occasionally be seen in transthyretin (familial) forms of amyloidosis (22; 04). Pinto and colleagues have shown that myopathy can be the early manifestation of wild-type ATTR amyloidosis and can either appear earlier than the peripheral neuropathy or occur after liver transplant in hereditary ATTR amyloidosis (38).

Amyloid is mostly deposited in connective tissue; that is, around the basal lamina of blood vessels, in nodules, or between parenchymal cells. This distribution is seen in nerve, skeletal muscle, and heart muscle (07; 50; 41). The skeletal muscle is also infiltrated as a rule in patients with amyloid polyneuropathy (11). The deposits arise without obvious cause or from monoclonal serum proteins in a plasma cell dyscrasia. The cause of organ damage or skeletal muscle dysfunction in amyloidosis is unclear but is most likely due to the direct toxic effects of amyloid. Other hypotheses include mechanical interference of muscle function by amyloid, ischemic atrophy of muscle caused by accumulation of amyloid in vessels, or amyloid accumulating within or on the sarcolemmal membrane and interfering with electrical conduction along the muscle fiber (10; 21).

Amyloid deposition has been recognized histopathologically as causing compression atrophy of muscle fibers and ischemic atrophy owing to extreme narrowing of capillaries when muscle pseudohypertrophy is not present (41). One of the possible pathophysiological mechanisms in amyloid myopathy is mechanical disruption of the sarcolemma by the abutting amyloid fibrils (23).

The pathological features of progressive amyloid myopathy associated with primary systemic amyloidosis are distinct from the intracellular amyloid deposits characteristic of sporadic inclusion body myositis and inherited inclusion body myopathy (33). Inclusion body myositis is an inflammatory myopathy characterized pathologically by rimmed vacuoles and the accumulation of amyloid-related proteins (18). The frequency of the diagnosis of amyloid myopathy increased 10-fold with the use of fluorescent Congo red stain as a routine procedure in assessing muscle biopsy specimens (51). Congo red-stained sections revealed infiltration of blood vessel walls and endomysium with amyloid protein as well as an unusual pattern of pathologic changes to muscle fibers. Congo red-stained sections of muscle biopsy viewed under fluorescent or polarized optics, and serum or urine protein immunoelectrophoresis, play an important role in the evaluation of myopathy (05). Neurologic manifestations of amyloidosis may precede involvement of other organs by several years; therefore, recognizing amyloid neuropathy and myopathy is essential as we have effective therapies for light chain (AL) and transthyretin (ATTR) neuropathy (34).

Anoctaminopathy-5 and dysferlinopathy were recognized as causes of isolated amyloid myopathy. Isolated amyloid myopathy accounts for almost a quarter of patients with amyloid myopathy, predominantly due to anoctaminopathy-5 (25).

Diagnostic workup

Diagnostic tools include analysis of serum and urine, electromyography, imaging, and histological investigation of appropriate tissue.

A monoclonal protein is often found by immunoelectrophoresis of serum and urine. An important clue to the recognition of this disease, particularly when pseudohypertrophy is not present, is the demonstration of a monoclonal gammopathy in serum or urine. Immunoelectrophoresis or immunofixation should be considered mandatory in the evaluation of a patient with myopathy. Immunoelectrophoresis of serum and urine should be a routine diagnostic test during the evaluation of myopathy of unknown cause.

Skeletal amyloidosis has been evaluated by CT, MRI, technetium-99m methylene diphosphonate, and technetium 99m-pyrophosphate (19; 56; 58). The MR appearance of amyloid myopathy differs from that of other neuromuscular conditions in the minimal changes found in muscle. The MRI in amyloid myopathy has a striking abnormality with marked reticulation of the subcutaneous fat (31). Unique findings on the MRI can alert the clinician to the diagnosis of amyloidosis prior to the muscle biopsy (17). Quantitative turnover studies can measure the total body burden of amyloid and can show whether amyloid deposits are being mobilized after chemotherapy (16).

The utility of MRI has significantly increased to target affected muscles for biopsy as well as to assess disease activity (31). It has been hypothesized that the high calcium content of amyloid deposits that binds the serum amyloid P component also binds the radionuclide. Scintigraphic studies with radioiodinated serum amyloid P component have been used to evaluate amyloid deposits in vivo. The use of MRI for the evaluation of inflammatory myopathies and neuromuscular disorders has become increasingly common, especially in cases of polymyositis (17; 30). Conventional MRI sequences do not appear to be sensitive for the detection of amyloid deposition; however, MRI can be helpful in displaying hypertrophy of adductor magnus and reticular STIR hyperintensity (54).

None of the procedures are diagnostic, and biopsy is still required to confirm the diagnosis. Invasive techniques can be less or more invasive based on the type used. Less invasive techniques include rectal biopsy or subcutaneous fat aspirate. Muscle biopsy is essential in the diagnostic evaluation of possible polymyositis because metabolic abnormalities, muscular dystrophies, drug-induced changes, inclusion-body myopathy, dermatomyositis, and amyloid myopathies can be overlooked.

In one of the series, the prevalence rate of amyloid myopathy in muscle biopsy specimens was low. Most of the muscles showed neurogenic features histologically. All concomitant sural nerve biopsy specimens contained amyloid, and most showed a predominance of axonopathic changes. When suspecting amyloid myopathy, Congo red staining and an immunohistochemistry or immunofluorescence assay should be performed. In middle-aged patients with progressive myopathy or muscle pain of unclear cause, amyloid should be considered with muscle biopsy as the definite test (39; 30).

Amyloid myopathy (Congo red staining)

(A) Congo red; (B) Congo red (polarized light); (C) Congo red fluorescence. (Contributed by Dr. Jasvinder Chawla.)

Acquired and hereditary amyloidosis can be definitively distinguished from one another only by immunohistochemical staining or molecular genetic testing (48).

References

01: Ashe J, Borel CO, Hart G, Humphrey RL, Derrick DA, Kuncl RW. Amyloid myopathy presenting with respiratory failure. J Neurol Neurosurg Psychiatry 1992;55(2):162-5. PMID 1538226
02: Bruni J, Bilbao JM, Pritzker KP. Myopathy associated with amyloid angiopathy. Can J Neurol Sci 1977;4:77-80. PMID 837267
03: Bumma N, Kahwash R, Parikh SV, et al. Multidisciplinary amyloidosis care in the era of personalized medicine. Front Neurol 2022;13:935936. PMID 36341129
04: Carr AS, Pelayo-Negro AL, Jaunmuktane Z, et al. Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy. Neuromuscul Disord 2015;25(6):511-5. PMID 25819286
05: Chapin JE, Kornfeld M, Harris A. Amyloid myopathy: characteristic features of a still underdiagnosed disease. Muscle Nerve 2005;31:266-72. PMID 15478123
06: Chawla J. Stepwise approach to myopathy in systemic disease. Front Neurol 2011;2:49. PMID 21886637
07: Cohen AS, Rubinow A. Amyloid polyneuropathy. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R, editors. Peripheral Neuropathy. Vol. 2. Philadelphia: WB Saunders, 1984:1866-98.
08: Dalakas MC, Cunningham G. Characterization of amyloid deposits in biopsies of 15 patients with "sporadic" (nonfamilial or plasma cell dyscrasic) amyloid polyneuropathy. Acta Neuropathol 1986;69(1):66-72. PMID 3008491
09: Das A, Mahadevan A, Kishore A, Shankar SK. A case of amyloid myopathy masquerading as inflammatory myopathy. Neurol India 2010;58(2):325-6. PMID 20508365
10: Doriguzzi C, Mongini T, Troni W, Monga G. Early sarcolemmal dysfunction in skeletal muscle amyloidosis. J Neurol 1987;234:52-4. PMID 3819787
11: Engel AG, Banker BQ, editors. Myology. New York: McGraw-Hill Book Co., 1986:1033.
12: Fisher JH, Thomson RA. Primary amyloidosis. Can Med Assoc J 1958;78:264-6. PMID 13511290
13: Gaspar B, Singh R, Mehta S, et al. Amyloid myopathy: an underdiagnosed entity. Neurol India 2016;64(5):1052-5. PMID 27625259
14: Gertz MA, Kyle RA. Myopathy in primary systemic amyloidosis. J Neurol Neurosurg Psychiatry 1996;60:655-60. PMID 8648333
15: Ghosh PS, Thaera GM, Tracy JA. Teaching neuroimages: dyspnea as a presenting manifestation of amyloid myopathy. Neurology 2013;81(24):e184. PMID 24323446
16: Hawkins PN. Studies with radiolabeled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin Sci (Lond) 1994;87(3):289-95. PMID 7955904
17: Hull ME, Griffith L, Kuncl RW, Wigley FM. A deceptive case of amyloid myopathy: clinical and magnetic resonance imaging features. Arthritis Rheum 2001;8:1954-8. PMID 11508448
18: Inamori Y, Higuchi I, Inoue T, et al. Inclusion body myositis coexisting with hypertrophic cardiomyopathy: an autopsy study. Neuromuscul Disord 2012;22(8):747-54. PMID 22560514
19: Jennekens FG, Wokke JH. Proximal weakness of the extremities as main feature of amyloid myopathy. Neurol Neurosurg Psychiatry 1987;50:1353-8. PMID 3681315
20: Karacostas D, Soumpourou M, Mavromatis I, et al. Isolated myopathy as the initial manifestation of primary systemic amyloidosis. J Neurol 2005;252:853-4. PMID 15742103
21: Kelly JJ. Neurologic complications of primary systemic amyloidosis. Rev Neurol Dis 2006;3(4):173-81. PMID 17224900
22: Kyle RA, Gertz MA. Systemic amyloidosis. Crit Rev Oncol Hematol 1990;10:49-87. PMID 2183811
23: Kyriakides T, Marquez B, Panousopoulos A, Kyriacou E, Kyriacou K. Amyloid myopathy: evidence for mechanical injury to the sarcolemma. Clin Neuropathol 2002;21(4):145-8. PMID 12143925
24: Lange RK. Primary amyloidosis of muscle. South Med J 1970;63:321-3. PMID 5415185
25: Liewluck T, Milone M. Characterization of isolated amyloid myopathy. Eur J Neurol 2017;24(12):1437-45. PMID 28888072
26: Lubarsch O. Zur Kenntnis ungewohnlicher Amyloidablagerungen. Virchows Arch Pathol Anat Histol 1929;271:867-89.
27: Mandl LA, Folkerth RD, Pick MA, et al. Amyloid myopathy masquerading as polymyositis. J Rheumatol 2000;27:949-52. PMID 10782821
28: Manoli I, Kwan JY, Wang Q, et al. Chronic myopathy due to immunoglobulin light chain amyloidosis. Mol Genet Metab. 2013;108(4):249-54. PMID 23465863
29: Martin JJ, Van Bogaert L, Van Damme L, Peremans E. Sur unepseudo-myopathie ligneuse generalisee par amyloidose primaire endomysio-vasculaire. J Neurol Sci 1970;11(2):147-66. PMID 5456544
30: Mercuri E, Pichiecchio A, Allsop J, et al. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging 2007;25:433-40. PMID 17260395
31: Metzler JP, Fleckenstein JL, White CL III, Haller RG, Frenkel EP, Greenlee RG Jr. MRI evaluation of amyloid myopathy. Skeletal Radiol 1992;21:463-5. PMID 1439899
32: Moore S, Symmons DP, DuPlessis D, Chinoy H. Amyloid myopathy masquerading as polymyositis. Clin Exp Rheumatol 2015;33(4):590-1. PMID 26120960
33: Nadkarni N, Freimer M, Mendell JR. Amyloidosis causing a progressive myopathy. Muscle Nerve 1995;18(9):1016-8. PMID 7643863
34: Namiranian D, Geisler S. Neuromuscular complications of systemic amyloidosis. Am J Med 2022;135 Suppl 1:S13-9. PMID 35104443
35: Nicolau S, Liewluck T, Milone M. Myopathies with finger flexor weakness: not only inclusion-body myositis. Muscle Nerve 2020;62(4):445-54. PMID 32478919
36: Ohtsuka Y, Yasui N, Sekiguchi K, et al. A case of amyloidosis with amyloid deposition detected only in skeletal muscles [Article in Japanese]. Rinsho Shinkeigaku 2012;52(10):739-43. PMID 23064623
37: Pinto MV, Dyck PJB, Liewluck T. Neuromuscular amyloidosis: unmasking the master of disguise. Muscle Nerve 2021;64(1):23-36. PMID 33458861
38: Pinto MV, Milone M, Mauermann ML, et al. Transthyretin amyloidosis: putting myopathy on the map. Muscle Nerve 2020;61(1):95-100. PMID 31587306
39: Prayson RA. Amyloid myopathy: clinicopathologic study of 16 cases. Hum Pathol 1998;29:463-8. PMID 9596269
40: Ringel SP, Claman HN. Amyloid associated muscle pseudohypertrophy. Arch Neurol 1982;39:413-7. PMID 7103772
41: Roke ME, Brown WF, Boughner D, Ang LC, Rice GP. Myopathy in primary systemic amyloidosis. Can Neurol Sci 1988;15:314-6. PMID 3061627
42: Rubin DI, Hermann RC. Electrophysiologic findings in amyloid myopathy. Muscle Nerve 1999;22:355-9. PMID 10086896
43: Santiago RM, Scharnhorst D, Ratkin G, Crouch EC. Respiratory muscle weakness and ventilatory failure in AL amyloidosis with muscular pseudohypertrophy. Am J Med 1987;83:175-8. PMID 3111259
44: Santos MS, Soares B, Mendes O, Carvalho CM, Casimiro RF. Multiple myeloma-amyloidosis presenting as pseudomyopathy. Rev Bras Reumatol 2011;51(6):651-4. PMID 22124598
45: Schneider BF, Normansell D, Ayers CR, Hess CE. Intermittent claudication as the presenting symptom in primary amyloidosis. Acta Haematol 1993;90:106-7. PMID 8285016
46: Scola RH, Werneck LC, Ramos CS, Pasquini R, Graf H, Arruda WO. Amyloidotic muscle pseudohypertrophy: case report. Arq Neuropsiquiatr 2001;59(3-A):582-6. PMID 11588639
47: Sheehan-Dare RA, Simmons AV. Amyloid myopathy and myeloma: response to treatment. Postgrad Med 1987;63:141-2. PMID 3671242
48: Simmons Z, Specht CS. The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis 2010;11(3):145-57. PMID 20215989
49: Smestad C, Monstad P, Lindboe CF, Mygland A. Amyloid myopathy presenting with distal atrophic weakness. Muscle Nerve 2004;29(4):605-7. PMID 15052628
50: Smith TJ, Kyle RA. Clinical significance of histopathological patterns of cardiac amyloidosis. Mayo Clin Proc 1984;59:547-55. PMID 6748745
51: Spuler S, Emslie-Smith A, Engel AG. Amyloid myopathy: an underdiagnosed entity. Ann Neurol 1998;43(6):719-28. PMID 9629841
52: Streeten EA, de la Monte SM, Kennedy TP. Amyloid infiltration of the diaphragm as a cause of respiratory failure. Chest 1986;89:760-2. PMID 3698711
53: Tanabe H, Maki Y, Urabe S, Higuchi I, Obayashi K, Hokezu Y. Myopathy in a patient with systemic AA amyloidosis possibly induced by psoriasis vulgaris: an autopsy case. Muscle Nerve 2015;52(6):1113-7. PMID 26179325
54: Tasca G, Modoni A, Nicoletti T, Monforte M, Cuccaro A, Ricci E. Muscle hypertrophy in amyloid myopathy. Neuromuscul Dis 2019;29(2):150-1. PMID 30704860
55: Trotter JL, Engel WK, Ignaczak TF. Amyloidosis with plasma cell dyscrasia: an overlooked cause of adult onset sensorimotor neuropathy. Arch Neurol 1977;34:209-14. PMID 843255
56: Urban BA, Fishman EK, Goldman SM, et al. CT evaluation of amyloidosis: spectrum of disease. Radiographics 1993;13:1295-308. PMID 8290725
57: Whitaker JN, Hashimoto K, Quinones M. Skeletal muscle pseudohypertrophy in primary amyloidosis. Neurology 1977;27(1):47-54. PMID 189252
58: Worsley DF, Lentle BC. Uptake of technetium-99m MDP in primary amyloidosis with a review of the mechanisms of soft tissue localization of bone seeking radiopharmaceuticals. J Nucl Med 1993;34:1612-5. PMID 8355083

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Jasvinder Chawla MD MBA

Dr. Chawla of Loyola University Medical Center has no relevant financial relationships to disclose.
See Profile

Editor

Michael K Hehir MD

Dr. Hehir of University of Vermont Medical Center received a consulting fee from Immunovant, Janssen, and UCB Pharma.
See Profile

Former Authors

Emma Ciafaloni MD FAAN

Patient Profile

Age range of presentation: 45 to 65+ years
Sex preponderance: male>female, >4:1
Heredity: Heredity may be a factor for familial amyloidosis related disorders
Population groups selectively affected: None selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Muscle disease or syndrome: 359.9

Symptomatic inflammatory myopathy in diseases classified elsewhere: 359.6

Other inflammatory and immune myopathies: 359.79

Amyloidosis, unspecified: 277.30

Muscle weakness, generalized: 728.87
ICD-10: Myopathy, unspecified: G72.9

Myopathy in diseases classified elsewhere: G73.7

Other inflammatory and immune myopathies, not elsewhere classified: G72.49

Amyloidosis, unspecified: E85.9

Muscle weakness (generalized): M62.81
OMIM: Amyloidosis, hereditary, transthyretin-related: #105210

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Amyloid myopathy

Associated Disorders

Peripheral neuropathy
Systemic amyloidosis

Differential Diagnosis

proximal limb muscle weakness without pseudohypertrophy
finger flexor weakness
inflammatory myopathies
drug- and toxin-induced myopathies
infectious myopathies
- endocrine myopathies
- muscular dystrophies
- anterior horn cell disease (progressive muscular atrophy)
- Lambert-Eaton myasthenic syndrome
- familial amyloid polyneuropathy
- pseudohypertrophy
- amyloidosis

Also Relevant

Dermatomyositis
Distal myopathies
Hereditary amyloid polyneuropathy
Inclusion-body myositis
Neuromuscular pathology: overview
- Primary systemic amyloidosis: neurologic complications

Clinical Categories

Neuromuscular Disorders

Amyloid myopathy …

Amyloid myopathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Congenital muscular dystrophy: merosin deficient form

Myoclonus epilepsy with ragged-red fibers

Core myopathies

Neurogenetics and genetic and genomic testing

Asymptomatic hyperCKemia

Limb-girdle muscular dystrophies

Chronic progressive external ophthalmoplegia

Drug-induced myasthenic syndromes

Amyloid myopathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Congenital muscular dystrophy: merosin deficient form

Myoclonus epilepsy with ragged-red fibers

Core myopathies

Neurogenetics and genetic and genomic testing

Asymptomatic hyperCKemia

Limb-girdle muscular dystrophies

Chronic progressive external ophthalmoplegia

Drug-induced myasthenic syndromes

This is an article preview.
Start a Free Account
to access the full version.